Exercise or conversion by Theresa Wingrove of 27788 shares of ImmunoGen subject to Rule 16b-3
About 67% of ImmunoGen's investor base is looking to short. The analysis of current outlook of investing in ImmunoGen suggests that many traders are alarmed regarding ImmunoGen's prospects. ImmunoGen's investing sentiment overview a quick insight into current market opportunities from investing in ImmunoGen. Many technical investors use ImmunoGen stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
ImmunoGen |
Filed transaction by Immunogen Inc officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
Read at macroaxis.com
ImmunoGen Fundamental Analysis
We analyze ImmunoGen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmunoGen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmunoGen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
ImmunoGen is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
ImmunoGen Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ImmunoGen stock to make a market-neutral strategy. Peer analysis of ImmunoGen could also be used in its relative valuation, which is a method of valuing ImmunoGen by comparing valuation metrics with similar companies.
Peers
ImmunoGen Related Equities
ELEV | Elevation Oncology | 4.69 | ||||
TERN | Terns Pharmaceuticals | 3.10 | ||||
TGTX | TG Therapeutics | 0.99 | ||||
HOOK | Hookipa Pharma | 0.52 | ||||
MCRB | Seres Therapeutics | 1.27 | ||||
INZY | Inozyme Pharma | 1.32 | ||||
MDGL | Madrigal Pharmaceuticals | 2.85 | ||||
PDSB | PDS Biotechnology | 3.13 | ||||
MREO | Mereo BioPharma | 3.43 | ||||
AXSM | Axsome Therapeutics | 3.95 | ||||
AKRO | Akero Therapeutics | 4.53 | ||||
HEPA | Hepion Pharmaceuticals | 5.88 | ||||
VKTX | Viking Therapeutics | 6.09 | ||||
XFOR | X4 Pharmaceuticals | 11.29 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |